First clinical case of boron neutron capture therapy for head and neck malignancies using <sup>18</sup>F‐BPA PET

Aihara, Teruhito; Hoshino, Junichi; Morita, Norimasa; Uno, Masako; Sakurai, Yoshinori; Maruhashi, Akira; Ono, Koji; Hashizume, Tamotsu

doi:10.1002/hed.20418

Cited by 117 publications

(57 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher amounts suitable for treatment have also not shown significant toxicity. 17,[37][38][39] In all 3 patients, the amount of 10 B measured in the tumor by PGRS was lower than anticipated, not reaching the value defined as ''favorable'' in the protocol. This is in clear contradiction to all published data reporting 10 B-concentration ratios of tumor to normal tissues of >2.…”

Section: L-para-boronophenylalaninementioning

confidence: 65%

“…This is in clear contradiction to all published data reporting 10 B-concentration ratios of tumor to normal tissues of >2. 17,27,[37][38][39] It might be argued that due to the high metabolic activity of the liver, the uptake of BPA in liver is higher than in brain, skin or other relevant organs at risk leading to decreased ratios between metastases and liver. This hypothesis however is not supported by the data published by Pinelli et al, who reported a 10 B-concentration ratio between metastasis/liver of 5.9 in the first patient treated in Pavia.…”

Section: L-para-boronophenylalaninementioning

confidence: 99%

“…12 It was used in clinical trials to treat glioblastoma and melanoma [13][14][15] and combined with BSH in squamous cell carcinoma of head and neck. 16,17 Since 1986, a research program at the University of Pavia (Italy) has been underway to investigate the possibility to cure diffuse hepatic metastases by explanting the liver and irradiating the organ with BNCT followed by an autotransplantation. [18][19][20][21] Within this program, 2 patients have been treated achieving tumor remission.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Uptake of two ¹⁰B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Wittig

Malagó

Collette

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Disseminated metastases of colorectal cancer in liver are incurable. The trial EORTC 11001 investigates whether autotransplantation after extracorporeal irradiation of the liver by boron neutron capture therapy (BNCT) might become a curative treatment option because of selective uptake of the compounds sodium mercaptoundecahydro-closo-dodecaborate (BSH) or L-para-boronophenylalanine (BPA). BSH (50 mg/kg bw) or BPA (100 mg/kg bw) were infused into patients who subsequently underwent resection of hepatic metastases. Blood and tissue samples were analyzed for the 10 B-concentration with prompt gamma ray spectroscopy (PGRS). Three patients received BSH and 3 received BPA. Adverse effects from the boron carriers did not occur. For BSH, the highest 10 B-concentration was observed in liver (31.5 6 2.7 lg/ g) followed by blood (24.8 6 4.7 lg/g) and tumor (23.2 6 2.1 lg/g) with a mean 10 B-concentration ratio metastasis/liver of 0.72 6 0.07. For BPA, the highest 10 B-concentration was measured in metastases (12.1 6 2.2 lg/g) followed by liver (8.5 6 0.5 lg/g) and blood (5.8 6 0.8 lg/g). As BPA is transported actively into cells, viable, metabolically active cells accumulate exclusively this compound. Consequently, a model is proposed to adjust the values measured by PGRS for the proportion of viable cells to express the relevant 10 B-concentration in the tumor cells, revealing a 10 Bconcentration ratio metastasis/liver of 6.8 6 1.7. In conclusion, BSH is not suitable as 10 B-carrier in liver metastases as the 10 Bconcentration in liver was higher compared to metastasis. BPA accumulates in hepatic metastases to an extent that allows for extracorporeal irradiation of the liver with BNCT. ' 2007 Wiley-Liss, Inc.

show abstract

Section: L-para-boronophenylalaninementioning

confidence: 65%

Section: L-para-boronophenylalaninementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Uptake of two ¹⁰B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Wittig

Malagó

Collette

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…10 (3). It was used in clinical trials to treat glioblastoma and melanoma (10 -12) and in combination with BSH to treat squamous cell carcinoma of head and neck (13,14).…”

Section: Animals and Tumorsmentioning

confidence: 99%

Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Wittig¹,

Arlinghaus

Kriegeskotte

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The exact intracellular localization and distribution of molecules and elements becomes increasingly important for the development of targeted therapies and contrast agents. We show that laser postionization secondary neutral mass spectrometry (laser-SNMS) is well suited to localize particular elements and small molecules with subcellular spatial resolution applying the technique exemplary to Boron Neutron Capture Therapy (BNCT). We showed in a murine sarcoma that the drugs used for clinical BNCT, namely L-para-boronophenylalanine (700 mg/kg body weight i.p.) and sodium mercaptoundecahydrocloso-dodecaborate (200 mg/kg body weight i.p.), transport the therapeutic agent 10 B into the cytoplasm and into the nucleus itself, the most sensitive area of the cell. Sodium mercaptoundecahydro-closo-dodecaborate distributes 10 B homogeneously and L-para-boronophenylalanine heterogeneously. When combining laser-SNMS with prompt ;-ray analysis as a screening technique, strategies for BNCT can be elaborated to develop new drugs or to improve the use of existing drugs on scientifically based evidence. The study shows the power of laser-SNMS in the early stages of drug development, also outside BNCT.

show abstract

“…Results from a few small series (11)(12)(13) and case reports (14,15) suggest that BNCT is effective in the treatment of locally recurrent head-and-neck cancer, and that most tumors respond to BNCT.…”

Section: Introductionmentioning

confidence: 99%

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial

Kankaanranta

Seppälä

Koivunoro

et al. 2012

International Journal of Radiation Oncology*Biology*Physics

213

182

View full text Add to dashboard Cite

First clinical case of boron neutron capture therapy for head and neck malignancies using ¹⁸F‐BPA PET

Abstract: Although only 1 patient has shown complete regression and additional long-term follow-up should be required to assess this treatment, we believe that head and neck tumors are suitable for BNCT and that such excellent results will have a great impact on patients in the near future.

Cited by 117 publications

References 68 publications

Uptake of two ¹⁰B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Uptake of two ¹⁰B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial

Contact Info

Product

Resources

About

First clinical case of boron neutron capture therapy for head and neck malignancies using 18F‐BPA PET

Abstract: Although only 1 patient has shown complete regression and additional long-term follow-up should be required to assess this treatment, we believe that head and neck tumors are suitable for BNCT and that such excellent results will have a great impact on patients in the near future.

Cited by 117 publications

References 68 publications

Uptake of two 10B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Uptake of two 10B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial

Contact Info

Product

Resources

About

First clinical case of boron neutron capture therapy for head and neck malignancies using ¹⁸F‐BPA PET

Uptake of two ¹⁰B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

Uptake of two ¹⁰B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)